| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 05/15/2008 | CA2668603A1 Microorganisms or fractions thereof capable of activating cellular immunity against carbohydrates |
| 05/15/2008 | CA2668346A1 Targeting of alpha-1 or alpha-3 subunit of na+, k+-atpase in the treatment of proliferative diseases |
| 05/15/2008 | CA2668282A1 Caspase inhibitors based on pyridazinone scaffold |
| 05/15/2008 | CA2668190A1 Compounds and compositions as protein kinase inhibitors |
| 05/15/2008 | CA2667487A1 Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors |
| 05/15/2008 | CA2667345A1 Solid forms comprising 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol, compositions thereof, and uses therewith |
| 05/14/2008 | EP1921094A2 Method for presenting and removing substances |
| 05/14/2008 | EP1921088A2 Peptides and related molecules that bind to tall-1 |
| 05/14/2008 | EP1921086A1 Antitumor agent |
| 05/14/2008 | EP1921080A1 Subsitituted 8-piperidinyl-2-pyridinyl-pyrimido(1,2-a)pyrimidin-6-one and 8-piperidinyl-2-pyrimidinyl-pyrimido(1,2-a)pyrimidin-6-one derivatives |
| 05/14/2008 | EP1921078A1 Multikinase inhibitor |
| 05/14/2008 | EP1921073A1 1,2,4-Triazole derivatives as sigma receptor inhibitors |
| 05/14/2008 | EP1921071A1 1,2,3- triazole derivatives as sigma receptor inhibitors |
| 05/14/2008 | EP1921070A1 Bicyclic heterocycles, medicaments comprising them, their use and process for their preparation |
| 05/14/2008 | EP1921066A1 Pyridylphenol compound and use thereof |
| 05/14/2008 | EP1920782A1 Carboyhdrate specific cellular immunity inducing microorganisms and fractions thereof |
| 05/14/2008 | EP1920781A1 Compositions comprising a core-1 positive microorganism and their use for the treatment or prophylaxis of tumors |
| 05/14/2008 | EP1920775A1 5'Triphosphate oligonucleotide induces anti-viral response |
| 05/14/2008 | EP1920773A1 Compositions for inhibition of anglogenesis |
| 05/14/2008 | EP1920370A2 Drug, drug guidance system, magnetic detection system, and drug design method |
| 05/14/2008 | EP1920066A1 Cancerous disease modifying antibodies |
| 05/14/2008 | EP1920056A1 Compositions and methods for treating breast cancer |
| 05/14/2008 | EP1919979A1 Polymer conjugates of k-252a and derivatives thereof |
| 05/14/2008 | EP1919957A2 Cd33-specific single-chain immunotoxin and method of use |
| 05/14/2008 | EP1919955A1 Cancerous disease modifying antibodies |
| 05/14/2008 | EP1919954A2 Immunomodulating tumor necrosis factor receptor 25 (tnfr25) agonists, antagonists and immunotoxins |
| 05/14/2008 | EP1919953A1 Antibodies directed against a ldl receptor |
| 05/14/2008 | EP1919920A2 Pentacyclic kinase inhibitors |
| 05/14/2008 | EP1919916A1 Condensed imidazolo derivatives for the inhibition of aldosterone synthase and aromatase |
| 05/14/2008 | EP1919910A1 Azabenzimidazole derivatives, their manufacture and use as anti-cancer agents |
| 05/14/2008 | EP1919906A1 3, 5-disubstituted pyrid-2-ones useful as inhibitors of tec family of non-receptor tyrosine kinases |
| 05/14/2008 | EP1919905A2 3,5-disubstituted pyrid-2-ones useful as inhibitors of tec family of non-recptor tyrosine kinases |
| 05/14/2008 | EP1919893A2 Polymorphic forms of imatinib mesylate and processes for their preparation as well as of amorphous imatinib mesylate and form alpha |
| 05/14/2008 | EP1919891A1 3,5-disubstituted pyrid-2-ones useful as inhibitors of tec family of non-receptor tyrosine kinases |
| 05/14/2008 | EP1919882A2 Isoxazole combretastatin derivatives for the treatment of proliferative disorders |
| 05/14/2008 | EP1919881A1 1, 2, 3 -triazoles inhibitors of tubulin polymerization for the treatment of poliferative disorders |
| 05/14/2008 | EP1919873A1 Fredericamycin derivatives |
| 05/14/2008 | EP1919868A2 New hybrid oligomers. their preparation process and pharmaceutical compositions containing them |
| 05/14/2008 | EP1919863A1 Process for the production of bicalutamide |
| 05/14/2008 | EP1919564A2 Compounds and methods for the treatment of cancer |
| 05/14/2008 | EP1919513A1 Target vector with activable imaging function |
| 05/14/2008 | EP1919480A2 Hedgehog pathway antagonists to treat disease |
| 05/14/2008 | EP1919464A1 Oxadiazole compounds as urokinase inhibitors |
| 05/14/2008 | EP1919463A2 Use of hif 1alfa modulators for treatment of cancer |
| 05/14/2008 | EP1919459A1 Solid pharmaceutical composition comprising 1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine and a ph modifier |
| 05/14/2008 | EP1667991B1 Quinazoline derivatives as tyrosine kinase inhibitors |
| 05/14/2008 | EP1664013B1 Calcilytic compounds |
| 05/14/2008 | EP1572087B1 Antibodies against cancer antigen tmeff2 and uses thereof |
| 05/14/2008 | EP1485365B1 Sulfonyl-derivatives as novel inhibitors of histone deacetylase |
| 05/14/2008 | EP1465900B1 Rho-kinase inhibitors |
| 05/14/2008 | EP1453531B1 Use of hmgb proteins and nucleic acids that code therefor |
| 05/14/2008 | EP1421084B1 Polycyclic guanine phosphodiesterase v inhibitors |
| 05/14/2008 | EP1264821B1 Novel crystal of stilbene derivative and process for producing the same |
| 05/14/2008 | EP1250455B1 Antisense inhibition of ptp1b expression |
| 05/14/2008 | EP1242592B1 A molecular switch for regulating mammalian gene expression |
| 05/14/2008 | EP1235934B1 Screening method for candidate drugs |
| 05/14/2008 | EP1087997B1 Monoclonal antibodies directed against the g3bp protein, and uses |
| 05/14/2008 | EP1017418B1 Vaccine composition for preventing or treating c hepatitis |
| 05/14/2008 | EP0961591B1 Method to enhance tissue accumulation of radiolabeled compounds |
| 05/14/2008 | EP0783313B1 Cdr-grafted type iii anti-cea humanized mouse monoclonal antibodies |
| 05/14/2008 | EP0772437B9 Compositions for delivery of genetic material |
| 05/14/2008 | CN101180293A Naphthalamide derivatives having antiproliferative activity |
| 05/14/2008 | CN101180292A 2-azetidinyl-4-(lH-pyrazol-3-ylamino)pyrimidines as inhibitors of insulin-like growth factor-i receptor activity |
| 05/14/2008 | CN101180275A Pyridine, and pyridazine derivatives |
| 05/14/2008 | CN101180096A Method and composition for treating mucosal disorders |
| 05/14/2008 | CN101180061A Compounds, and compositions containing the compounds, and method for treatment of metastatic melanoma and other cancers |
| 05/14/2008 | CN101180060A Combination of pyrimidylaminobenzamide compounds and imatinib for treating or preventing proliferative diseases |
| 05/14/2008 | CN101180055A Combination therapy comprising diaryl ureas for treating diseases |
| 05/14/2008 | CN101180054A Medical uses of 39-desmethoxyrapamycin and analogues thereof |
| 05/14/2008 | CN101180053A Treatment of liver diseases in which iron plays a role in pathogenesis |
| 05/14/2008 | CN101180049A Nutritive composition for treating sarcoma and prostate cancer |
| 05/14/2008 | CN101177681A Rhabdophis tigrina snake uncoupling protein gene-SB and uses thereof |
| 05/14/2008 | CN101177453A Recombined chimeric antibody against human tumor necrosis factor alpha |
| 05/14/2008 | CN101177449A Furca polypeptide, drug composition and use thereof |
| 05/14/2008 | CN101177445A Novel bufadienolide compound as well as preparation method and uses thereof |
| 05/14/2008 | CN101177435A Cyanidenon ammino platinum anti-cancer drugs and method for making same |
| 05/14/2008 | CN101177434A Meletin ammino platinum anti-cancer drugs and method for making same |
| 05/14/2008 | CN101177429A Topoisomerase enzyme inhibitor, preparation method and use thereof |
| 05/14/2008 | CN101177426A Process for separating extracting spherosinin from gansu whin |
| 05/14/2008 | CN101177425A Novel epothilones compound as well as preparation method and use thereof |
| 05/14/2008 | CN101177421A Method for preparing high-purity taxone compounds |
| 05/14/2008 | CN101177415A Method for preparing new crystal form of anti-cancer compound ZD1839 |
| 05/14/2008 | CN101177414A New crystal form of anti-cancer compound ZD1839, preparation method thereof and medical compound containing the crystal form |
| 05/14/2008 | CN101176787A Method for chemoprevention of prostate cancer |
| 05/14/2008 | CN101176784A Application of compounds methionine enkephalin for preparing medicine for curing blood medulla hematopoietic system cancer |
| 05/14/2008 | CN101176755A Application of meletin-7-0-glycoside in mass control of cudrania tricuspidata or preparations thereof |
| 05/14/2008 | CN101176744A Phyton medicine for curing chronic granulocytic leukemia |
| 05/14/2008 | CN101176739A Toadpoison ligand extract as well as preparation method and application thereof |
| 05/14/2008 | CN101176724A Oxymatrine or matrine sustained-release pellet and preparation method thereof |
| 05/14/2008 | CN101176721A Hexamethylmelamine liposome and preparation method thereof |
| 05/14/2008 | CN101176719A Paclitaxel/multialkene paclitaxel liposome composite medicine and preparation method thereof |
| 05/14/2008 | CN101176717A Temperature control gel rubber sustained-release injection containing resist metabolism series medicine |
| 05/14/2008 | CN101176716A Sunitinib sustained-release implantation agent for curing entity tumour |
| 05/14/2008 | CN101176715A Gefitinib sustained-release implantation agent for curing entity tumour |
| 05/14/2008 | CN101176714A Meifaron sustained-release implantation agent for curing entity tumour |
| 05/14/2008 | CN101176713A Carmustine sustained-release implantation agent for curing entity tumour |
| 05/14/2008 | CN101176712A Nimustine sustained-release implantation agent for curing entity tumour |
| 05/14/2008 | CN101176711A Yitarbisin sustained-release implantation agent for curing entity tumour |
| 05/14/2008 | CN101176710A Mitoxantrone sustained-release implantation agent for curing entity tumour |
| 05/14/2008 | CN101176709A Beisalutin sustained-release implantation agent for curing entity tumour |